Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
FAAH-IN-2
Cat. No.:
OB0225LY-0450
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
FAAH-IN-2 is a selective fatty acid amide hydrolase (FAAH) inhibitor that enhances endogenous cannabinoid activity.
Synonym:
O-Desmorpholinopropyl gefitinib; 184475-71-6; 4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-ol; 4-(3-Chloro-4-fluoro-anilino)-7-methoxy-quinazolin-6-ol; 4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinol
CAS No.:
184475-71-6
Compound CID:
10471217
Formula:
C15H11ClFN3O2
Formula Weight:
319.72
Specification
Relative Density:
1.49 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
FAAH-IN-2 can be used in studies of endogenous cannabinoid signaling or play an important role in models of nociceptive hypersensitivity.
Library Information
Targets:
Metabolic enzymes
Receptors:
FAAH
Pathways:
Metabolism; Autophagy; Neuronal signaling
Plate Number:
AOCL-6
Plate Location:
g7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
50 mg/mL; 156.39 mM
ALogP:
4.088
HBA_Count:
3
HBD_Count:
2
Rotatable Bond:
3
